|
Cytogeneticsa
|
IRD (N = 127)
|
RD (N = 217)
|
p1
|
|---|
|
t(4;14), n (%)
|
n = 59
|
n = 86
| |
|
Negative
|
53 (89.8%)
|
80 (93.0%)
|
0.548
|
|
Positive
|
6 (10.2%)
|
6 (7.0%)
|
|
t(14;16), n (%)
|
n = 52
|
n = 69
| |
|
Negative
|
49 (94.2%)
|
66 (95.7%)
|
1.000
|
|
Positive
|
3 (5.8%)
|
3 (4.3%)
|
|
del(17p13), n (%)
|
n = 66
|
n = 91
| |
|
Negative
|
58 (87.9%)
|
79 (86.8%)
|
1.000
|
|
Positive
|
8 (12.1%)
|
12 (13.2%)
|
|
Cytogenetics - risk groupsb, n (%)
|
n = 54
|
n = 77
| |
|
Standard risk
|
39 (72.2%)
|
58 (75.3%)
|
0.691
|
|
High risk
|
15 (27.8%)
|
19 (24.7%)
|
- a Only cytogenetics evaluated at diagnosis before treatment initiation included. Cytogenetics assessed in 69% of IRD patients (87/127) and 49% of RD patients (106/217) but most patients did not have all required parameters assessed. The table contains only the three major risk aberrations
- b “standard risk” = negative t(4;14) and t(14;16) and del(17p13); “high risk” = positive at least one of these aberrations
- 1 p-value of Fisher’s exact test for categorical variables
